EAJF.F VALIRX PLC LS-001

Healthcare Biotechnology Frankfurt Exchange
0.0005 EUR
Close of Nov 11, 2026
0.0005 0.0040
Market cap
EUR 660K
P/E
-
P/B
0.18x
ROE
-78.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is EAJF.F undervalued?

Graham number

The Graham number of VALIRX PLC LS-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VALIRX PLC LS-001 fundamental analysis

No fundamental analysis for VALIRX PLC LS-001 yet.

VALIRX PLC LS-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VALIRX PLC LS-001

ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical t…

Full company profile